BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. $(BIIB)$ and UCB have announced the presentation of additional detailed results from their Phase 3 PHOENYCS GO study at the European Alliance of Associations for Rheumatology's annual meeting (EULAR 2025) in Barcelona, Spain. The study evaluates dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, in patients with moderate-to-severe systemic lupus erythematosus $(SLE)$. The results demonstrated significant clinical improvements in disease activity, including fatigue and disease activity/remission, as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Dapirolizumab pegol is not yet approved for use in SLE by any regulatory authority, and a second Phase 3 trial is ongoing to confirm these findings.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.